Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Lightstone Ventures is a venture capital firm founded in 2012, with operations in the United States and Ireland. The firm has raised a total of approximately $850 million across multiple funds, with its latest fund, Fund III, closing at $375 million in 2021. Lightstone Ventures focuses on investing in innovative therapeutics and technologies within the life sciences sector, particularly in biotech and medtech. The firm has a portfolio of seven companies, showcasing its commitment to high-impact investments.
The team at Lightstone Ventures boasts nearly 100 years of combined operational experience, which enables them to support companies at various stages of growth, from pre-seed to commercialization. The firm is recognized for its strategic guidance and extensive industry connections, which help portfolio companies navigate the complexities of the biotech and medtech landscapes. Lightstone Ventures has achieved notable milestones, including successful exits and significant funding rounds for its portfolio companies.
Lightstone Ventures operates from its offices in the United States and Ireland, with a focus on building partnerships that drive innovation in therapeutics. The firm is affiliated with Lightstone Group, a diversified real estate and investment conglomerate, which may provide additional resources and support for its investment activities.
Lightstone Ventures targets investments in the biotech and medtech sectors, specifically focusing on companies that develop first-in-class drugs and groundbreaking medical technologies. Their investment strategy is thesis-driven, emphasizing disruptive technologies across various disease areas, including central nervous system disorders, immunology, oncology, and ophthalmology. The firm seeks to partner with founders who leverage data analytics and scientific platforms to drive innovation.
Investment stages range from pre-seed to growth equity, allowing Lightstone Ventures to engage with companies at different points in their development. The firm typically invests in companies that are developing novel and disruptive technologies aimed at transforming patient outcomes. They are particularly interested in founders with ambitious ideas that merge technology, medicine, and consumer health, especially in personalized medicine and targeted therapeutics.
Lightstone Ventures prefers to invest in companies that demonstrate a clear path to commercialization and have the potential to address significant unmet medical needs. Their approach includes providing strategic guidance, access to a network of experts, and support in navigating the complexities of the biotech and medtech landscapes.
Lightstone Ventures has a diverse portfolio of seven companies, each focused on innovative solutions in the biotech and healthcare sectors. Notable portfolio companies include:
Lightstone Ventures has a strong track record of supporting companies that are at the forefront of medical innovation, with a focus on high-impact therapeutics and technologies.
Christina Isacson, Ph.D. - Partner: Christina joined Lightstone Ventures with the close of Fund III in 2021. She has extensive experience in the biotech sector and has been involved in numerous successful investments.
Young Kwon, Ph.D. - Operating Partner: Young also joined with Fund III in 2021 and brings a wealth of knowledge in operational management and strategic development within the life sciences.
Caroline Gaynor - Partner: Caroline leads the Ireland office and was elected Chair of the Irish Venture Capital and Private Equity Association in August 2025. She has a strong background in venture capital and has been instrumental in expanding Lightstone's presence in Europe.
H. Martin Seidel, Ph.D. - Advisor: H. Martin joined in January 2025 and supports biopharmaceutical deal sourcing and diligence, leveraging his extensive network in the industry.
José-Alain Sahel, M.D. - Advisor: José-Alain joined in April 2024 and specializes in ophthalmology and biopharma, providing valuable insights into investments in these areas.
Hong I. Wan - CEO and Advisor: Hong is a key figure in the firm, known for his strategic vision and commitment to supporting innovative therapeutics.
Conor Hanley - Fire1: Conor is involved in developing innovative healthcare solutions and contributes to the firm's investment strategy.
Susan Molineaux - CEO and Advisor: Susan plays a crucial role in guiding portfolio companies and ensuring alignment with Lightstone's investment thesis.
Karun D. Naga - The Foundry, LLC: Karun brings expertise in startup development and operational excellence to the team.
To pitch to Lightstone Ventures, founders should use the contact form available on their website at lightstonevc.com. It is important to include a comprehensive deck that outlines the business model, market opportunity, and team qualifications. Response times may vary, but founders are encouraged to follow up if they do not receive a timely reply.
Lightstone Ventures operates the 65LAB program, a strategic investment initiative in a Singapore-based incubator partnered with Evotec. This program aims to grow a pipeline of investible therapeutic companies originating from research institutions in Singapore. Founders interested in this program should inquire through the Lightstone Ventures website for eligibility and application details.
In 2025, Lightstone Ventures has been highly active, with portfolio companies closing approximately $725 million in private financing rounds alongside premier co-investors. Notable recent rounds include:
Lightstone Ventures has also participated in notable exits, including the acquisition of Disarm Therapeutics by Eli Lilly and the acquisition of Ra Pharmaceuticals by UCB. The firm continues to build its reputation as a leading investor in the biotech and medtech sectors.
What are Lightstone Ventures' investment criteria?
Lightstone Ventures invests in early-stage biotech and medtech companies that are developing disruptive technologies aimed at transforming patient outcomes. They focus on sectors such as central nervous system disorders, immunology, oncology, and ophthalmology.
How can founders apply or pitch to Lightstone Ventures?
Founders can pitch their ideas through the Lightstone Ventures website at lightstonevc.com. It is advisable to include a detailed deck that outlines the business model, market opportunity, and team background.
What makes Lightstone Ventures different from other VC firms?
Lightstone Ventures is distinguished by its thesis-driven investment strategy and its focus on high-impact therapeutics. The firm has nearly 100 years of combined operational experience, which allows them to provide strategic guidance and support to portfolio companies.
What is the geographic scope of Lightstone Ventures?
The firm operates primarily in the United States and Ireland, targeting innovative companies in these regions.
What is the typical check size for investments?
Lightstone Ventures invests across various stages, including pre-seed, seed, Series A, Series B, and growth equity, with check sizes varying accordingly.
What kind of post-investment involvement does Lightstone Ventures have?
Lightstone Ventures provides ongoing support to its portfolio companies through strategic guidance, access to a network of experts, and assistance in navigating the complexities of the biotech and medtech landscapes.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.